Press releases

SYNTAX trial will compare the performance of drug-eluting stents with cardiac surgery in the most complex patient subsets.

Award recognizes Company's accomplishments in creating a project-based system.

(April 7, 2005) -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2005 on Tuesday, April 19, at 11:00...

A live webcast and replay of the April 12 conference session will be available.

Launch of Company's three large vessel TAXUS stent systems completes its line of sizes available in Europe and international markets.

With the indication, patients receiving the stent systems may safely undergo Magnetic Resonance Imaging (MRI) examination immediately following implantation.

Precision™ Spinal Cord Stimulation (SCS) System is a powerful new technology that provides many chronic pain sufferers a treatment option that is comfortable, long lasting and effective.

Company no longer markets or sells the NIR stent; findings will not affect Boston Scientific's ability to sell its market-leading TAXUS stent systems.

Company's Quincy Distribution Center approved as a sterilization site for its Cutting Balloon™ microsurgical dilatation device product line.

Company recognized for its achievements in lean manufacturing at its Minnesota facility